U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C22H26O4
Molecular Weight 354.4403
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SERATRODAST

SMILES

CC1=C(C)C(=O)C(=C(C)C1=O)C(CCCCCC(=O)O)c2ccccc2

InChI

InChIKey=ZBVKEHDGYSLCCC-UHFFFAOYSA-N
InChI=1S/C22H26O4/c1-14-15(2)22(26)20(16(3)21(14)25)18(17-10-6-4-7-11-17)12-8-5-9-13-19(23)24/h4,6-7,10-11,18H,5,8-9,12-13H2,1-3H3,(H,23,24)

HIDE SMILES / InChI

Molecular Formula C22H26O4
Molecular Weight 354.4403
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Description
Curator's Comment:: https://www.1mg.com/drugs/seretra-80-mg-tablet-130697

Seratrodast belongs to a class of medication called thromboxane A2/prostaglandin endoperoxide receptor antagonist. Seratrodast blocks the broncho-constrictor effects of certain chemicals (prostaglandins) in the body. Seratrodast also decreases the inflammation by antagonising the thromboxane A2 receptor. Adverse effects include gastrointestinal disturbances, drowsiness, headache, palpitations, and hepatitis. Seradair may interact with Ozagrel.

Originator

Curator's Comment:: # Takeda Chemical Industries, Ltd.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
60 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Bronica

Approved Use

Seratrodast is used for the prevention and treatment of mild to moderate asthma.
PubMed

PubMed

TitleDatePubMed
Mechanisms underlying cerebrovascular effects of cigarette smoking in rats in vivo.
1998 Aug
Long-term observations of the clinical course after step down of corticosteroid inhalation therapy in adult chronic asthmatics: correlation with serum levels of eosinophil cationic protein.
2002 Sep
Patents

Sample Use Guides

In Vivo Use Guide
Curator's Comment:: In elderly patients it is recommended that the treatment should be started with a lower dose of 40 mg/day.
It is given in single doses of 80 mg in the evening after food.
Route of Administration: Oral
In Vitro Use Guide
Sources: DOI: 10.1111/j.1527-3466.1996.tb00231.x
Seratrodast competitively inhibited the contractile response to U-46619, PGD2, 9-alpha, 11beta-PGF2, or PGF2-alpha with pA2 values of 7.69, 7.20, 7.79, and 5.71, respectively.
Substance Class Chemical
Created
by admin
on Fri Jun 25 21:55:13 UTC 2021
Edited
by admin
on Fri Jun 25 21:55:13 UTC 2021
Record UNII
4U58JM421N
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
SERATRODAST
INN   JAN   MART.   MI   USAN   WHO-DD  
INN   USAN  
Official Name English
SERATRODAST [JAN]
Common Name English
(+/-)-2,4,5-TRIMETHYL-3,6-DIOXO-.ZETA.-PHENYL-1,4-CYCLOHEXADIENE-1-HEPTANOIC ACID
Systematic Name English
ABBOTT 73001
Code English
SERATRODAST [WHO-DD]
Common Name English
AA-2414
Code English
BRONICA
Brand Name English
SERATRODAST [MI]
Common Name English
SERATRODAST [INN]
Common Name English
ABBOTT-73001
Code English
ABT-001
Code English
BENZENEHEPTANOIC ACID, .ZETA.-(2,4,5-TRIMETHYL-3,6-DIOXO-1,4-CYCLOHEXADIEN-1-YL)-, (+/-)-
Common Name English
NSC-759640
Code English
(+/-)-7-(3,5,6-TRIMETHYL-1,4-BENZOQUINON-2-YL)-7-PHENYLHEPTANOIC ACID
Systematic Name English
SERATRODAST [USAN]
Common Name English
SERATRODAST [MART.]
Common Name English
A-73001
Code English
Classification Tree Code System Code
WHO-ATC R03DX06
Created by admin on Fri Jun 25 21:55:13 UTC 2021 , Edited by admin on Fri Jun 25 21:55:13 UTC 2021
WHO-VATC QR03DX06
Created by admin on Fri Jun 25 21:55:13 UTC 2021 , Edited by admin on Fri Jun 25 21:55:13 UTC 2021
NCI_THESAURUS C29712
Created by admin on Fri Jun 25 21:55:13 UTC 2021 , Edited by admin on Fri Jun 25 21:55:13 UTC 2021
Code System Code Type Description
FDA UNII
4U58JM421N
Created by admin on Fri Jun 25 21:55:13 UTC 2021 , Edited by admin on Fri Jun 25 21:55:13 UTC 2021
PRIMARY
EPA CompTox
112665-43-7
Created by admin on Fri Jun 25 21:55:13 UTC 2021 , Edited by admin on Fri Jun 25 21:55:13 UTC 2021
PRIMARY
ChEMBL
CHEMBL70972
Created by admin on Fri Jun 25 21:55:13 UTC 2021 , Edited by admin on Fri Jun 25 21:55:13 UTC 2021
PRIMARY
WIKIPEDIA
SERATRODAST
Created by admin on Fri Jun 25 21:55:13 UTC 2021 , Edited by admin on Fri Jun 25 21:55:13 UTC 2021
PRIMARY
NCI_THESAURUS
C90671
Created by admin on Fri Jun 25 21:55:13 UTC 2021 , Edited by admin on Fri Jun 25 21:55:13 UTC 2021
PRIMARY
DRUG CENTRAL
2432
Created by admin on Fri Jun 25 21:55:13 UTC 2021 , Edited by admin on Fri Jun 25 21:55:13 UTC 2021
PRIMARY
EVMPD
SUB10490MIG
Created by admin on Fri Jun 25 21:55:13 UTC 2021 , Edited by admin on Fri Jun 25 21:55:13 UTC 2021
PRIMARY
CAS
112665-43-7
Created by admin on Fri Jun 25 21:55:13 UTC 2021 , Edited by admin on Fri Jun 25 21:55:13 UTC 2021
PRIMARY
MERCK INDEX
M9868
Created by admin on Fri Jun 25 21:55:13 UTC 2021 , Edited by admin on Fri Jun 25 21:55:13 UTC 2021
PRIMARY Merck Index
INN
7069
Created by admin on Fri Jun 25 21:55:13 UTC 2021 , Edited by admin on Fri Jun 25 21:55:13 UTC 2021
PRIMARY
PUBCHEM
2449
Created by admin on Fri Jun 25 21:55:13 UTC 2021 , Edited by admin on Fri Jun 25 21:55:13 UTC 2021
PRIMARY
MESH
C060230
Created by admin on Fri Jun 25 21:55:13 UTC 2021 , Edited by admin on Fri Jun 25 21:55:13 UTC 2021
PRIMARY
DRUG BANK
DB06739
Created by admin on Fri Jun 25 21:55:13 UTC 2021 , Edited by admin on Fri Jun 25 21:55:13 UTC 2021
PRIMARY
Related Record Type Details
TARGET -> INHIBITOR
POTENCY
METABOLIC ENZYME -> SUBSTRATE
METABOLIC ENZYME -> SUBSTRATE
METABOLIC ENZYME -> SUBSTRATE
METABOLIC ENZYME -> SUBSTRATE
Related Record Type Details
METABOLITE -> PARENT
in human liver microsomes
MAJOR
METABOLITE -> PARENT
in human liver microsomes
MINOR
Related Record Type Details
ACTIVE MOIETY